Cite
Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer.
MLA
Schuetz, Matthias, et al. “Evaluating Repetitive 18F-Fluoroazomycin-Arabinoside (18FAZA) PET in the Setting of MRI Guided Adaptive Radiotherapy in Cervical Cancer.” Acta Oncologica, vol. 49, no. 7, Oct. 2010, pp. 941–47. EBSCOhost, https://doi.org/10.3109/0284186X.2010.510145.
APA
Schuetz, M., Schmid, M. P., Pötter, R., Kommata, S., Georg, D., Lukic, D., Dudczak, R., Kletter, K., Dimopoulos, J., Karanikas, G., & Bachtiary, B. (2010). Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncologica, 49(7), 941–947. https://doi.org/10.3109/0284186X.2010.510145
Chicago
Schuetz, Matthias, Maximilian P. Schmid, Richard Pötter, Spyridoula Kommata, Dietmar Georg, Dobrica Lukic, Robert Dudczak, et al. 2010. “Evaluating Repetitive 18F-Fluoroazomycin-Arabinoside (18FAZA) PET in the Setting of MRI Guided Adaptive Radiotherapy in Cervical Cancer.” Acta Oncologica 49 (7): 941–47. doi:10.3109/0284186X.2010.510145.